A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

Lignende værker

• A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a C. muridarum challenge
  af: Cheng, Chunmei, et al.
  Udgivet: (2013)
• Vaccination with the Recombinant Major Outer Membrane Protein Elicits Antibodies to the Constant Domains and Induces Cross-Serovar Protection against Intranasal Challenge with Chlamydia trachomatis
  af: Tifrea, Delia F., et al.
  Udgivet: (2013)
• Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin
  af: Cheng, Chunmei, et al.
  Udgivet: (2009)
• Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization
  af: Ralli-Jain, Pooja, et al.
  Udgivet: (2010)
• Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model
  af: Cheng, Chunmei, et al.
  Udgivet: (2011)